Niki BioSolutions' subsidiary, DiamiR Biosciences, secured a commercial agreement with Charter Research to provide APOE genotyping services. This deal expands DiamiR's commercial reach and positions its testing platform within clinical trials for neurodegenerative diseases, potentially increasing revenue and market visibility for Niki BioSolutions.
Niki BioSolutions announced that its subsidiary, DiamiR Biosciences, has signed an agreement with Charter Research to perform APOE genotyping. This is a positive development for Niki BioSolutions as it represents a new commercial contract for its DiamiR subsidiary, leveraging its CAP-accredited and NYS CLEP-approved testing platform. The deal positions DiamiR's services within a multi-site clinical research organization, which could lead to increased revenue and broader adoption of its technology, especially given the critical role of APOE status in neurodegeneration clinical trials. In the short term, this provides a modest boost to Niki's commercial prospects. Long-term, it could open doors to further collaborations and establish DiamiR as a key player in genetic testing for neurodegenerative research. For traders, this presents an opportunity to monitor NIKI for potential growth driven by increased commercial activity and validation of its subsidiary's technology.